<DOC>
	<DOCNO>NCT00436280</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question : - To assess whether Enzastaurin combine rituximab , gemcitabine oxaliplatin ( R-GEMOX ) help patient Diffuse Large B-Cell Lymphoma remain free disease thus live longer . - To assess side effect might associate enzastaurin R-GEMOX . - To look characteristic level certain gene protein learn DLBCL enzastaurin work body . - To look level enzastaurin body long remain .</brief_summary>
	<brief_title>Chemotherapy Patients With Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis DLBCL transform ( CD20+ ) indolent lymphoma Relapsed/progressed response obtain 1st 2ndline treatment , patient progress SD obtain 1st 2ndline . Measurable disease ( lymph node great 1.5 cm ) Adequate organ function Greater equal 60 year less 60 ( great equal 18 year ) eligible HDC ASCT Prior Allogeneic transplantation More 2 prior anticancer treatment regimens Pregnant breastfeed Humanimmunodeficiencyvirus ( HIV ) associate lymphomas Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>